Van Tuyl Christopher 4

What Happened

• Christopher Van Tuyl, Chief Legal Officer of Immunovant (IMVT), sold 5,165 shares in an open-market/private sale on April 8, 2026 for a weighted average price of $24.83, generating proceeds of approximately $128,247. This sale was to satisfy tax withholding tied to RSUs that vested and was not a discretionary sell decision.

Key Details

• Transaction date: April 8, 2026; Form 4 filed April 10, 2026 (filed two days after the trade).
• Transaction type/code: Sale (S); proceeds ≈ $128,247.
• Price: weighted average $24.83; individual trade prices ranged from $24.54 to $25.39 (see footnote F2).
• RSU background: On April 1, 2025 the reporting person was granted 50,787 RSUs; 12,696 RSUs vested on April 1, 2026. The 5,165 shares sold were to cover tax withholding on that vesting (footnote F1).
• Shares owned after transaction: Not specified in the summary filing — see the Form 4 for total beneficial ownership details.
• Filing timeliness: Reported within two business days of the transaction (timely).

Context

• This was a "sell-to-cover" tax withholding sale tied to vested restricted stock units, which companies often mandate; such transactions typically reflect tax obligations rather than a judgment about the company's prospects. The filer offers to provide, upon request, the breakdown of how many shares sold at each price within the reported range.